Last updated: April 30, 2024
Sponsor: Seoul National University Bundang Hospital
Overall Status: Active - Recruiting
Phase
4
Condition
Dyslipidemia
Diabetes Mellitus, Type 2
Diabetes Prevention
Treatment
Choline fenofibrate
Policosanol
Clinical Study ID
NCT05365425
B-2111-720-003
Ages > 20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit
- Male or female of 20 years or over
- Mixed dyslipidemia: triglyceride 200~499 mg/dL, HDL-cholesterol male ≤45 mg/dL orfemale ≤50 mg/dL
- Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm
- Creatinine ≤1.8 mg/dL
Exclusion
Exclusion Criteria:
- Dyslipidemia which requires other therapy: triglyceride ≥500 mg/dL or LDL-cholesterol ≥190 mg/dL
- Uncontrolled hypertension
- Severe renal dysfunction
- GOT/GPT >120/120 or chronic liver disease
- Pregnant or childbearing woman who does not have enough contraception
- Changes of medication related to chronic diseases (diabetes, hypertension,dyslipidemia, etc.) within 3 months
- Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)
Study Design
Total Participants: 56
Treatment Group(s): 2
Primary Treatment: Choline fenofibrate
Phase: 4
Study Start date:
June 01, 2023
Estimated Completion Date:
December 31, 2026
Study Description
Connect with a study center
SNUBH
Seongnam, Gyeonggi 13620
Korea, Republic ofActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.